New hope for Hard-to-Treat myeloma: QLS32015 enters phase 3 trial
NCT ID NCT07138209
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called QLS32015 against two standard treatment combinations (pomalidomide with dexamethasone or selinexor with dexamethasone) in 228 people with multiple myeloma that has relapsed or is refractory. The main goal is to see if QLS32015 can delay cancer progression better than the current options. Participants are randomly assigned to receive either the new drug or one of the standard regimens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLS32015
What this could lead to
If successful, QLS32015 could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not be more effective or safer than existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Clinical Research Center for Blood Diseases
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••